News & Events

September 2014 StreamLines Newsletter

StreamLines logo












The September 2014 StreamLines Newsletter can be found online here.


In This Issue:

Equinext, LLC launches its new Novobrace product at CVC Kansas City

Lexington, KY, August 20, 2014 - - Equinext, LLC, a company located on the Coldstream Research Campus, launches its new Novobrace (TM) product at CVC Kansas City, MO, Kansas City Convention Center, August 22 – 25, in partnership with Centaur Animal Health’s exhibit. 

Novobrace launches at CVC Kansas City, MO, Kansas City Convention Center, August 22 – 25, in partnership with Centaur Animal Health’s exhibit. CVC Kansas City is the premier CE (continuing education) convention for the veterinary community. Attendees have the opportunity to have dialogues about Novobrace case studies and case selections with field veterinarian, Maggie Nolin, MAB, DVM and Eric Hauck, CEO, Novobrace.
“The number of horses diagnosed with tendonitis and desmitis each year is staggering. Until now, there was no solution on the market that offered immediate clinical benefits like Novobrace provides. Novobrace creates a flexible, chemical brace to provide immediate stabilization to the injured tissue, prevents further propagation of the lesion, and results in the horse returning to full work significantly faster. We are pleased to bring our innovative product to the equine market in partnership with Centaur Animal Health at CVC Kansas City,” Novobrace CEO, Eric Hauck, said in a statement.
Field service veterinarian Maggie Nolin will present information about Novobrace success stories and discuss recommended treatment protocols, including the use of Novobrace as a first line treatment for tendonitis and desmitis and as an adjunct therapy with stem cell / platelet rich plasma therapies. “As a veterinarian and a horse owner, I look forward to discussing this exciting new technology with equine practitioners. Showing people case studies demonstrates the effectiveness of the product. Novobrace helps heal injuries and gets horses turned out faster than alternative therapies. CVC Kansas City is a great opportunity to share this information with colleagues ,” Maggie Nolin, MAB, DVM.
Visit the Centaur Animal Health in the exhibit hall (#1011) to meet with the Novobrace team to discuss this innovative product to treat equine tendonitis and desmitis.
About Novobrace (TM)
Our patented technology, Novobrace, is a chemically made flexible, internal brace formed by injection of a crosslinking agent which immediately adds mechanical support to the tendon or ligament.
This brace prevents further propagation of the lesion, provides better, stronger healing, and results in the horse returning to full work significantly faster. Novobrace may be used as a standalone treatment or as a complementary therapy. Clinical indications include the treatment of superficial digital tendons, deep digital flexor tendons and suspensory ligaments with or without lesion. Novobrace is a product of Equinext, LLC. For more information:
About Centaur Animal Health
Centaur Animal Health was founded in 1986 and is focused on developing innovative diagnostics, pharmaceuticals and nutraceuticals that address significant therapeutic needs for companion and production animals. Centaur licenses and develops patent-protected technologies from animal health or human pharmaceutical and biotechnology companies. Custom manufacturing is available in their FDA and DEA certified plant. For more information, please visit:
Equinext, LLC | Novobrace
859.317.6263 ext 701 / 859.421.0032
Equinext and Novobrace are registered trademarks of Equinext LLC. Other trademarks are owned by their respective companies.

Skana Aluminum and SECAT Partner for Success

LEXINGTON, Ky. (August 13, 2014) - Secat, Inc. is pleased to announce an agreement for testing services with Skana Aluminum Company located in Manitowoc, Wisconsin. The agreement between the two companies is to provide R&D, technical support and other services to Skana’s casting and rolling operations.
Skana Aluminum is a fully integrated rolling mill, complete with direct chill (DC) casting, hot and cold rolling, slitting, tension leveling and finished coil, sheet or circle capabilities. Skana is very efficient at casting small quantities of specialized alloys and higher volumes of more common alloys.
Secat, Inc. is world renowned in aluminum testing, research, failure analysis, product development, alloy development, and the enhancement of processes and properties. Secat is located on the Coldstream Research Campus in Lexington KY.

Tempur Sealy announces acquisition of Sealy brand rights In Japan

Tempur Sealy
LEXINGTON, Ky. (April 8, 2014) — Tempur Sealy International, Inc. (NYSE: TPX), the world’s largest bedding provider, has signed a definitive agreement to acquire the Sealy brand rights in Japan and certain assets from its former licensee. The company anticipates closing the transaction, which is subject to customary closing conditions, during its fiscal third quarter of 2014. Financial terms were not disclosed.
As part of the transaction, certain functions of the former licensee, including sales and marketing, will be integrated into the company’s Japanese subsidiary. In addition, the companies have executed a supply agreement, whereby the former licensee will become a contract manufacturer for certain Sealy branded products in Japan.
“New market expansion is one of our four key strategic growth initiatives and is also an important driver in our long-term international revenue synergies targets. The acquisition of Sealy brand rights in Japan is the first transaction whereby we have regained rights from a Sealy licensee arrangement,” said Tempur Sealy International, Inc. CEO Mark Sarvary. “Japan has been an important market for our company for a long time and we are excited at the prospects of further increasing our penetration and market share with a strengthened brand and product offering.”
Chief Financial Officer Dale Williams said, “As a result of this transaction, we anticipate Japan will soon be our largest market as measured by sales outside of North America. Given our current expectation for when the deal will close, we anticipate the transaction will be break-even to modestly accretive to earnings in 2014 and accretive thereafter.”

April 2014 StreamLines Newsletter

newsletter header


The April 2014 StreamLines Newsletter can be found online here.


In This Issue:

HDI Seminar on Facilitating Access for Students with Limited Communication Skills

LEXINGTON, Ky. (Jan. 16, 2014) — The Human Development Institute at the University of Kentucky (HDI) will present a free seminar about facilitating access for students with complex communication needs. 
“Communication First: Facilitating Access to the General Curriculum,” will be presented from 1-3 p.m. EST (noon -2 p.m. CST) Thursday, Feb. 27,  in the Human Development Training Room at UK's Coldstream Research Campus. Video-conference sites will be available around the city and at locations throughout the state.
All students communicate, although sometimes in very subtle behaviors that can be easily missed or in challenging behaviors that are quite obvious but fail to communicate to their educators, peers or parents. Evidence-based practice has found that, with direct instruction and augmentative communication most suited to their needs, students can gain communicative competence at a rapid rate.
Presenting will be Jacqueline Kearns, principal investigator of HDI's Teaching Age Appropriate Learning Through Communication (TAALC) Project, and Judith Page, associate professor in the Division of Communication Disorders in the UK College of Health Sciences.
Space is limited and registration is required. Those who wish to attend may register online. Attendance site must be selected at time of registration; if a site is full, you will have the option to select another site. HDI's seminar series is open to faculty, staff and students, as well as self-advocates, parents/caregivers and professionals statewide.
Continuing education units (CEUs) are approved for effective instructional leaders and social work, psychology and licensed professional counselors. The seminar is affiliated with the Kentucky Office of Vocational Rehabilitation for CEUs in Certified Rehabilitation Counseling. There is a $20 CEU fee for social workers, psychologists and licensed professional counselors.
If you wish to host a live video-conference for your community at your site, please contact Patti Naber Singleton, 859-257-4913. For general questions about the HDI Seminar Series, please contact Tina Lindon, 859-257-1714.
MEDIA CONTACT: Keith Hautala, 859-323-2396

New KNODE Portal Connects UK Researchers with Potential Collaborators

LEXINGTON, Ky. (Jan. 9, 2013) — The University of Kentucky is partnering with KNODE Inc. to promote and connect UK researchers with colleagues and potential collaborators worldwide.
Through a UK-specific portal, the KNODE platform helps individual researchers, academic institutions and companies share scientific knowledge, particularly in the biomedical field.
Anyone can create a free login to access UK’s portal and/or search the complete database that currently includes millions of researchers worldwide. Users can search by expert name, area of expertise or affiliation, with search results linking to next-generation expertise profiles automatically generated by KNODE’s advanced semantic mining and data processing algorithms.
Users can dynamically search and filter an expert’s scientific content (publications, patents, grants, and clinical trials), aggregated by KNODE’s platform from publically available databases (PubMed, USPTO, NIH RePORTER, Researchers with profiles in the system can also claim and edit their information, add links to university lab pages and make other enhancements.
"KNODE provides us a single, searchable gateway to the leading-edge biomedical research being conducted by our investigators and our collaborators in industry and academia," said UK Vice President for Research James W. Tracy. "Technology like this can spur vital scientific collaboration."
David Steinberg, KNODE's acting chief executive officer and partner at Boston-based PureTech Ventures, said, "There is a clear opportunity to develop exciting ways to automate and characterize researcher expertise, while also making these experts searchable and accessible in a new, powerful way. We are pleased to be working with the University of Kentucky to put their researchers and collaborators in the spotlight, highlighting their unique capabilities and scientific track record.”
In addition to adding the University of Kentucky to its growing list of academic partnerships, KNODE also recently announced a commercial partnership with Wiley, a leading international scientific publisher. The company also has formed partnerships with AstraZeneca and others to improve life sciences R&D efforts such as technology licensing and collaboration. KNODE is part of Enlight Biosciences LLC, created by PureTech Ventures in partnership with major pharmaceutical companies and academic supporters.
For more information on UK’s KNODE portal, visit
MEDIA CONTACT:  Keith Hautala, 859-323-2396 or

CBRE Cincinnati to Represent Proposed Data Center on the Coldstream Research Campus

November 18, 2013 
LEXINGTON, KY– Mike McMillan of CBRE Cincinnati's Data Center Solutions Group is representing KDC Real Estate Development & Investments' data center build-to-suit site located at the University of Kentucky's Coldstream Research Campus in Lexington, Kentucky.
Once pre-leasing reaches 20,000 square feet, the proposed data center site will be located on the beautiful 735-acre campus that is minutes away from UK and downtown Lexington. The Coldstream Research Campus is currently home to 66 organizations with more than 2,000 employees working in biotechnology, pharmaceuticals and equine health, and a variety of other industry sectors.
The proposed data center will not only support local businesses’ IT and computing needs but will also help the local community.
“Building a data center at this site will give local Lexington businesses a secure, flexible and scalable place for their computer equipment,” Mike McMillan, of the CBRE Data Center Solutions Group, said. “It will support new businesses looking to move to Lexington and also bring new jobs to the community.”
It will also save businesses' time and money because they won’t have to design, build and manage their own data center, McMillan said.
For more information, contact:
Mike McMillan | Vice President
CBRE | Data Solutions Group
T +1 513 369 1306
Joe Ludwig | Communication Specialist
CBRE | Americas Marketing
T +1 513 369 1305

ARPA-E Announces $608,863 Award to Phinx LLC for its Transformational Energy Research Project

Phinix LLC One of 33 Technologies in 18 States Working to Secure America’s Energy Future in Advanced Manufacturing  
Lexington, KY (October 9, 2013) — On September 19, 2013, Deputy Director Cheryl Martin announced that 33 breakthrough energy projects will receive approximately $66 million from the Advanced Research Projects Agency-Energy (ARPA-E) under two new programs that provide options for a more sustainable and secure American future.  One recipient, Lexington, KY based Phinix, LLC, has been awarded $608,863 for their project titled “Electrochemical Extraction of High Quality Magnesium from Scrap”. Phinix is located at the Coldstream Research Campus.
Phinix will develop a new electrochemical cell technology that can recover high-quality magnesium from aluminum-magnesium scrap.  This technology could lower costs, energy inputs, and emissions from magnesium production, expanding its use in transportation industries.  By recovering and reusing aluminum-magnesium scrap, Phinix’s technology could reduce the need for manufacturing new, expensive primary metals while developing a sustainable and low-cost advanced manufacturing process. 
Processing of aluminum-magnesium scarp to produce aluminum products used in beverage and transportation sectors is a key market driver for Kentucky’s economically significant aluminum industry employing over 15,000 men and women with high paying jobs.  
Deputy Director Martin made the project announcement during a roundtable discussion on Capitol Hill that focused on how American ingenuity and strategic public-private partnerships are driving U.S. energy innovation. 
Dr. Subodh Das will the Principal Investigator for this project. 
Dr. Subodh Das, CEO and Founder
Phinix, LLC

Coldstream Laboratories Awarded 5-Year Contract With the National Cancer Institute

Marketwired - Sep 24, 2013 - Coldstream Laboratories, Inc., a provider of sterile drug product development and manufacturing services, has announced that they have been awarded a 5-year contract with the National Cancer Institute ("NCI") under solicitation number N02CM37007-11 (contract# HHSN261201300031I) entitled "Development and Production of Parenteral Dosage Forms for Clinical Studies."
The contract lasts for five years with the objective of developing and producing pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products. The NCI has been a leader in field of cancer research since its establishment in 1937.
"The requirements for this program mesh perfectly with Coldstream's capabilities and facilities. We couldn't be more pleased to be awarded this opportunity to work with the NCI," said Eric W. Smart, Coldstream's President and Chief Executive Officer. "We work hard to ensure the highest degree of quality in everything we do and being awarded this contract indicates that we are succeeding. Being awarded this contract affords Coldstream the opportunity to continue to make an impact in the field of cancer research and help advance oncologic care for the millions of people impacted by cancer every year."
Coldstream Laboratories, Inc., based in Lexington, KY, is a privately held specialty pharmaceutical contract manufacturing organization. The company was formed in 2007 as a spin-off from the University of Kentucky's Center for Pharmaceutical Sciences and Technology. Coldstream operates Kentucky's only parenteral manufacturing facility.
Syndicate content